ReviewAging cell2016
Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic.
Review in Aging cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review.Frontiers in aging · 2023Pooled it
- Change in the Rate of Biological Aging in Response to Caloric Restriction: CALERIE Biobank Analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017Trial
- Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.International journal of molecular sciences · 2026Review
- Article
- Repurposing niclosamide to mitigate inflammaging: a review of multi-target mechanisms in cellular senescence and age-related decline.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Potential dietary geroprotectors and their impact on key mechanisms of aging.Biogerontology · 2025Review
- No winners or losers: clinical chemistry-based biological aging metrics perform similarly across cohorts and health outcomes.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Effects of Long-Term Moderate-Intensity Exercise on Autonomic Nervous System Dysfunction Induced by Cardiac Neurovascular Interface Deterioration.Reviews in cardiovascular medicine · 2025Review
- Toward precision interventions and metrics of inflammaging.Nature aging · 2025Review
- Calorie restriction mimetics against aging and inflammation.Biogerontology · 2025Review
- Topoisomerase inhibitor amonafide enhances defense responses to promote longevity in C. elegans.GeroScience · 2025Article
- Article
- An Expert Consensus Statement on Biomarkers of Aging for Use in Intervention Studies.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Review
- Towards Healthy Longevity: Comprehensive Insights from Molecular Targets and Biomarkers to Biological Clocks.International journal of molecular sciences · 2024Review
- Geroprotective potential of microbiome modulators in the Caenorhabditis elegans model.GeroScience · 2024Review
- Article
- Review
- Aging-Related Multisystem Dysregulation Over the Adult Life Span and Physical Function in Later Life: The Atherosclerosis Risk in Communities (ARIC) Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Studying the Geroprotective Properties of YAP/TAZ Signaling Inhibitors onInternational journal of molecular sciences · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the coming decades, a massive shift in the aging segment of the population will have major social and economic consequences around the world. One way to offset this increase is to expedite the development of geroprotectors, substances that slow aging, repair age-associated damage and extend healthy lifespan, or healthspan. While over 200 geroprotectors are now reported in model organisms and some are in human use for specific disease indications, the path toward determining whether they affect aging in humans remains obscure. Translation to the clinic is hampered by multiple issues including absence of a common set of criteria to define, select, and classify these substances, given the complexity of the aging process and their enormous diversity in mechanism of action. Translational research efforts would benefit from the formation of a scientific consensus on the following: the definition of 'geroprotector', the selection criteria for geroprotectors, a comprehensive classification system, and an analytical model. Here, we review current approaches to selection and put forth our own suggested selection criteria. Standardizing selection of geroprotectors will streamline discovery and analysis of new candidates, saving time and cost involved in translation to clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.